It has been recently suggested that activation of 5-HT4 receptors might possess antidepressant properties in rats after a 3 days treatment, indicating a new strategy for developing faster-acting antidepressants. In this regard, here we have evaluated in rat brain the expression of proteins related to neuroplasticity after a subacute RS67333 treatment and their correlate on behavioural paradigms. A 3-days treatment with RS67333 (1.5 mg/kg/day), previously shown to increase neurogenesis in dentate gyrus, induced an upregulation in the expression of BDNF (% increase = 64%; p < 0.05) and pCREB/CREB ratio (% increase = 93%; p < 0.01) in the hippocampus. A significant reduction in the forced swimming test (immobility time) was also observed after 3 (% red= 27%; p < 0.001) and 7 (% red=29%; P < 0.001) days of treatment. However, in the novelty-feeding suppressed test, a validated paradigm to predict chronic antidepressant efficacy, a significant reduction in the latency to feed (% red= 49%; p < 0.03) was observed only after 7 days of treatment. Short-term treatment with RS67333 also failed to downregulate 5-HT4 receptor-coupled adenylate cyclase activity. Our data suggest that neural proliferationrelated changes induced by antidepressants precede clinical improvement. Furthermore, when compared to data regarding classical antidepressants, our results show that the activation of 5-HT4 receptors could represent a good strategy for developing antidepressants with a minor onset of action.
